Analyst Ratings For Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Today, Cantor Fitzgerald raised its price target on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to $165.00 per share.
There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is Buy with a consensus target price of $44.8633 per share, a potential 212.85% upside.
Some recent analyst ratings include
- 12/17/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Buy rating reiterated by Chardan Capital with a $24.50 price target
- 10/17/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Outperform rating reiterated by William Blair
- 10/4/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) had its Overweight rating reiterated by Piper Jaffray Companies with a $25.00 price target
- 9/6/2018-Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) gets upgraded to Buy by B. Riley with a price target of $19.00
- On 12/12/2018 Christopher Richard Anzalone, CEO, sold 90,000 with an average share price of $14.07 per share and the total transaction amounting to $1,266,300.00.
- On 11/23/2018 Douglas B. Given, Director, sold 3,000 with an average share price of $12.74 per share and the total transaction amounting to $38,220.00.
- On 11/9/2018 Christopher Richard Anzalone, CEO, sold 81,500 with an average share price of $14.39 per share and the total transaction amounting to $1,172,785.00.
- On 10/19/2018 Peter Brian Leone, VP, sold 131,137 with an average share price of $13.49 per share and the total transaction amounting to $1,769,038.13.
- On 9/6/2018 Kenneth Allen Myszkowski, CFO, sold 45,000 with an average share price of $19.34 per share and the total transaction amounting to $870,300.00.
- On 9/4/2018 Christopher Richard Anzalone, CEO, sold 164,834 with an average share price of $14.45 per share and the total transaction amounting to $2,381,851.30.
- On 8/31/2018 Christopher Richard Anzalone, CEO, sold 100,000 with an average share price of $14.45 per share and the total transaction amounting to $1,445,000.00.
About Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its medicines include ARO-HBV, a Phase I/II subcutaneous ribonucleic acid interference(RNAi) therapy candidate that is used for the treatment of chronic hepatitis B viral infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Recent Trading Activity for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals Inc closed the previous trading session at 14,39 +0,070 0,49 % with 14.01 shares trading hands.